KetoTV reported on Thursday that Nicolas Tzenios plans to launch a keto clinical trial under a partnership with KGK Science Inc, a contract research organisation.
Hon Prof Dr Nicolas Tzenios is the chairman of medical research hub TRCGEN+. He is the author of 'Nic's Keto Diet', a book which is now available in four languages, and created a Keto postgraduate course that is taught in universities and colleges across the globe. TRCGEN+ sponsors medical research clinical trials including Keto diet effects and a genetic research related to specific genetic cancer treatment approach with Kursk State Medical University.
Through this research programme, Hon Prof Tzenios hopes to prove his 'Friendly LDL Theory', which suggests that in the absence of elevated glucose, low-density lipoprotein (LDL) does not oxidise or form plaque and has anti-inflammatory effects. He believes that elevated glucose, rather than fat, results in the onset of cardiovascular and diet-related diseases.
In addition, Hon Prof Tzenios is applying to patent his Friendly LDL Theory. This concept is inspired by the success of the keto diet, which involves the ingestion of high-fat, low-carb foods. If corroborated, his theory has the potential to greatly impact the realm of dietary science, KetoTV said.
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Corstasis and U.S. Heart and Vascular partner to advance heart failure care with ENBUMYST
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Merck reports positive Phase 3 results for oral PCSK9 inhibitor enlicitide
Abbott's Navitor TAVI system granted CE Mark for expanded indication
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
FDA lifts clinical hold on Rocket Pharmaceuticals' RP-A501 Phase 2 Danon disease trial
OptiBiotix signs distribution deal with major weight management company
Novartis to present cardiovascular abstracts portfolio data at ESC Congress in Madrid
LivaNova announces commercial launch of Essenz Perfusion System in China
Viatris' generic iron sucrose injection gains US FDA approval
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio